Donor White Blood Cell Infusion in Treating Patients With Metastatic or Unresectable Cancer

White Cell Transfer as Cancer Therapy

RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with cancer.

PURPOSE: This clinical trial is studying the side effects of donor white blood cell infusion in treating patients with metastatic or unresectable cancer.

Study Overview

• Status: Withdrawn
• Conditions: Unspecified Childhood Solid Tumor, Protocol Specific; Unspecified Adult Solid Tumor, Protocol Specific
• Intervention / Treatment: Genetic: polymerase chain reaction; Biological: leukocyte therapy

Detailed Description

OBJECTIVES:

Primary

• Determine the safety of white blood cell infusion in patients with metastatic or unresectable cancer.

Secondary

• Determine the efficacy of this therapy in these patients.

OUTLINE: Patients receive allogeneic white blood cell infusions once daily for 5-10 infusions.

Patients undergo blood sample collection periodically for correlative laboratory studies. The samples are evaluated by in vitro white cell kill assay before the first infusion, immediately after the first infusion, on day 2, and then immediately after the last infusion to assess in vitro cancer cell killing activity. Chimerism studies are performed before the first infusion, immediately after the first infusion, and then on days 2 and 7. Complete chimerism is assayed by short tandem repeat analysis using PCR. Patients with readily accessible tumor tissue (e.g., cervical or axillary lymph nodes or subcutaneous tumor nodules) may also undergo biopsy during the first week of treatment to demonstrate the presence or absence of tumor infiltrating granulocytes.

After completion of study therapy, patients are followed periodically for 3 months.

• Study Type: Interventional
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 120 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed malignancy

  • Metastatic or unresectable disease
  • Standard curative or palliative measures do not exist or are no longer effective

• Measurable or non-measurable disease

  • Measurable disease is defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan

  • Non-measurable disease is defined as all other lesions (including small lesions and truly non-measurable lesions), including any of the following:

    • Bone lesions
    • Ascites
    • Pleural/pericardial effusion
    • Lymphangitis cutis/pulmonis
    • Abdominal masses that are not confirmed and followed by imaging techniques
    • Cystic lesions
• No brain metastasis

• Healthy blood donor available meeting the following criteria:

  • Willing to be included in the White Cell Donor Registry created for this study
  • Willing to undergo granulocyte apheresis at the American Red Cross
  • ABO compatible with the patient
  • HLA-mismatched with the patient

  • Demonstrates ≥ 60% cytotoxic killing activity (CKA) as determined by in vitro white cell kill assay

    • Less than 60% CKA allowed if deemed suitable by the investigators

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Life expectancy ≥ 4 months
• ANC ≥ 1,000/µL
• Platelet count > 100,000/µL (platelet transfusion independent)
• Serum bilirubin ≤ 2 mg/dL
• AST and ALT < 3 times upper limit of normal
• Serum creatinine ≤ 2 mg/dL
• No uncontrolled diabetes mellitus
• No myocardial infarction within the past 30 days
• No active serious infection
• No HIV infection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Negative panel reactive antibody test (i.e., absence of serum HLA antibody)

PRIOR CONCURRENT THERAPY:

• No prior fludarabine phosphate
• No prior stem cell transplantation
• At least 4 weeks since prior medical therapy, radiotherapy, or surgery
• More than 30 days since prior immunosuppressive agents other than steroids

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Safety

Secondary Outcome Measures

Outcome Measure
Response (complete response, partial response, stable disease, or disease progression)

Collaborators and Investigators

• Sponsor: Wake Forest University Health Sciences
• Collaborators: National Cancer Institute (NCI)
• Investigators: Study Chair: Zheng Cui, MD, PhD, Wake Forest University Health Sciences

Study record dates

Study Registration Dates

• First Submitted: January 30, 2008
• First Submitted That Met QC Criteria: January 30, 2008
• First Posted (Estimate): February 6, 2008

Study Record Updates

• Last Update Posted (Estimate): January 19, 2017
• Last Update Submitted That Met QC Criteria: January 17, 2017
• Last Verified: June 1, 2013

More Information

Terms related to this study

• Keywords: unspecified childhood solid tumor, protocol specific; unspecified adult solid tumor, protocol specific
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: CCCWFU-99107; CDR0000584624 (Registry Identifier: PDQ (Physician Data Query)); IRB00002178